Sign in

CIK 0001658551

  • Non-accelerated filer
  • Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464600503
Phone
+1 617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$10,951,125
in 9 filings, $8.0M under 10b5-1 plans

Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-06-04 Quimi Daphne Director Grant or award · Stock Option (right to buy) +24,372 24,372
2025-06-05 Quimi Daphne Director Grant or award · Stock Option (right to buy) +25,000 25,000
2024-06-06 Quimi Daphne Director Grant or award · Stock Option (right to buy) +25,000 25,000
2024-05-15 Quimi Daphne Director Purchase +2,250 $1.89 $4K 5,000
2024-05-14 Quimi Daphne Director Purchase +2,750 $1.89 $5K 2,750
2023-06-08 Quimi Daphne Director Grant or award · Stock Option (right to buy) +16,985 16,985
2022-06-09 Quimi Daphne Director Grant or award · Stock Option (Right to Buy) +19,000 19,000
2022-01-06 Quimi Daphne Director Grant or award · Stock Option (Right to Buy) +8,400 8,400

Page 1 of 1 · 8 trades